Clinical Trial Update: KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for KYSA-3, an anti-CD19 CAR T-cell therapy, in subjects with refractory lupus nephritis (Phase 1/2; active/not recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• KYSA-3 (CD19-directed CAR T-cell therapy)

Snippet

Sponsor: Kyverna Therapeutics | Conditions: Lupus Nephritis, Lupus Nephritis - WHO Class III | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING